Quantinno Capital Management LP trimmed its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 18.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 115,100 shares of the company's stock after selling 25,496 shares during the period. Quantinno Capital Management LP's holdings in AstraZeneca were worth $7,541,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Banque Transatlantique SA acquired a new stake in shares of AstraZeneca in the fourth quarter valued at about $26,000. Albion Financial Group UT increased its position in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company's stock worth $40,000 after purchasing an additional 248 shares during the last quarter. CoreCap Advisors LLC increased its position in AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock worth $42,000 after purchasing an additional 155 shares during the last quarter. Golden State Wealth Management LLC acquired a new stake in AstraZeneca during the fourth quarter worth about $55,000. Finally, Crews Bank & Trust acquired a new stake in shares of AstraZeneca during the fourth quarter valued at about $55,000. 20.35% of the stock is owned by hedge funds and other institutional investors.
AstraZeneca Stock Up 1.3%
Shares of NASDAQ:AZN traded up $0.88 during trading on Monday, hitting $69.69. 5,315,941 shares of the company were exchanged, compared to its average volume of 5,186,266. The stock has a market capitalization of $216.13 billion, a P/E ratio of 30.84, a PEG ratio of 1.42 and a beta of 0.40. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The firm's 50 day moving average price is $70.46 and its 200-day moving average price is $69.44.
AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. AstraZeneca's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.06 EPS. On average, research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on AZN. Morgan Stanley began coverage on shares of AstraZeneca in a research report on Wednesday, February 12th. They set an "overweight" rating for the company. BNP Paribas began coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price objective for the company. Finally, UBS Group upgraded shares of AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $88.00.
Read Our Latest Stock Report on AZN
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
